1. Home
  2. HYPR vs RCEL Comparison

HYPR vs RCEL Comparison

Compare HYPR & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

HOLD

Current Price

$1.23

Market Cap

104.0M

Sector

Health Care

ML Signal

HOLD

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

HOLD

Current Price

$4.42

Market Cap

102.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HYPR
RCEL
Founded
2014
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
104.0M
102.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HYPR
RCEL
Price
$1.23
$4.42
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$1.28
$7.17
AVG Volume (30 Days)
541.0K
233.5K
Earning Date
03-16-2026
02-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$10,591,000.00
$72,401,000.00
Revenue This Year
$5.17
$13.61
Revenue Next Year
$35.44
$19.61
P/E Ratio
N/A
N/A
Revenue Growth
N/A
20.59
52 Week Low
$0.53
$3.22
52 Week High
$2.22
$11.25

Technical Indicators

Market Signals
Indicator
HYPR
RCEL
Relative Strength Index (RSI) 60.44 73.40
Support Level $1.14 $3.24
Resistance Level $1.31 $3.94
Average True Range (ATR) 0.09 0.23
MACD 0.02 0.11
Stochastic Oscillator 75.00 87.31

Price Performance

Historical Comparison
HYPR
RCEL

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: